There are two isoforms (LXRα and β) and LXRβ-KO mice are protected from hepatic steatosis despite elevated circulating GC levels and this has raised the potential of LXRβ as a therapeutic target to treat and prevent GC-induced hepatic steatosis [144]. This evidence concerns the gene NR1H2 and fatty liver disease.